By expanding our models from podocytes to other target cells of diabetes, we may provide insights into a potentially common energy-responsive AMPK-SP1-dynein–driven pathogenesis of multiple diabetic complications and the value of pharmaceutically remodeling this pathway to manage them. The gene discussed is SP1; the disease is diabetes mellitus.